Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-08-07
2007-08-07
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S069100, C435S320100, C435S325000
Reexamination Certificate
active
10291202
ABSTRACT:
The invention provides methods for establishing electrical coupling between cardiomyocytes and recombinant cells which have been genetically engineered to express a connexin protein such as connexin 43 (Cx43) protein. The invention is based on the discovery that genetic modification of skeletal muscle cells to express a recombinant connexin, enables the genetically modified cells to establish electrocommunication with cardiac cells via gap junctions. The recombinant connexin-expressing cells can be used for repair of cardiac tissue and for treatment of cardiac disease by transplantation into cardiac tissue.
REFERENCES:
patent: 5103821 (1992-04-01), King
patent: 5130141 (1992-07-01), Law et al.
patent: 5661133 (1997-08-01), Leiden et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5709854 (1998-01-01), Griffith-Cima et al.
patent: 6059726 (2000-05-01), Lee et al.
patent: 6110161 (2000-08-01), Mathiesen et al.
patent: 6129761 (2000-10-01), Hubbell
patent: 6151525 (2000-11-01), Soykan et al.
patent: 6238429 (2001-05-01), Markowitz et al.
patent: 6239117 (2001-05-01), Christ et al.
patent: 6387369 (2002-05-01), Pittenger et al.
patent: 6415178 (2002-07-01), Ben-Haim et al.
patent: 6932804 (2005-08-01), Lee
patent: 2001/0009986 (2001-07-01), Ponzi
patent: 2002/0013615 (2002-01-01), Haim et al.
patent: 2002/0031501 (2002-03-01), Law
patent: 2002/0044925 (2002-04-01), Law
patent: 2002/0061295 (2002-05-01), Field
patent: 2002/0061587 (2002-05-01), Anversa
patent: 2004/0098075 (2004-05-01), Lee
patent: 2006/0002898 (2006-01-01), Lee et al.
patent: WO 90/10471 (1990-09-01), None
patent: WO 96/18303 (1996-06-01), None
patent: WO 98/02150 (1998-01-01), None
patent: WO 99/15211 (1999-04-01), None
patent: WO 01/68814 (2001-09-01), None
patent: WO 02/33111 (2002-04-01), None
patent: WO 02/33111 (2002-04-01), None
patent: WO 03/039344 (2003-05-01), None
patent: WO 03/094697 (2003-11-01), None
patent: WO 03/094855 (2003-11-01), None
patent: WO 03/095016 (2003-11-01), None
patent: WO 2003/094697 (2003-11-01), None
patent: WO 2004/045709 (2004-06-01), None
patent: WO 2004/050013 (2004-06-01), None
Wang et al, J Thorac Cardiovasc Surg 2000; 120:999-1006.
Field, et al., “Electrophysiological Modulation of Cardiomyocytic Tissue by Transfected Fibroblasts Expressing Potassium Channels” Circulation. 105:522-529 (2002).
Long, et al., “The Cardiac Fibroblast, Another Therapeutic target for Mending the Broken Heart” J. Mol Cell Cardiol. 34; 1273-1278 (2002).
Murry, et al., “Muscle Cell Grafting for the Treatment and Prevention of Heart Failure” J. of Cardiac Failure vol. 8 No. 6 Suppl (2002).
Chachques, et al., “Cellular Therapy Reverses Myhocardial Dysfunction” 1stVirtual Congress of Cardiology. The American Association of Thoracic Surgery (Abst) 2000:202.
Yang et al. VEGF Enhances Functional Improvement of Postinfarcted Hearts By Transplantation of ESC-Differentiated Cells: J. Appl. Physiol. 2002, vol. 93, pp. 1140-1151.
Khurana et al. Gene Therapy For Cardiovascular Disease. A Case for Cautious Optimis. Hypertension 2001, vol. 38, pp. 1210-1216.
Nicholas et al., “Immunocytochemical Analysis of Connexin Expression in the Healthy and Diseased Cardiovascular System”, Microscopy Res. Technique. 2001, vol. 52, pp. 301-322.
Davis, et al., “Modulation of connexin43 expression: effects on cellular coupling”, Journal of Cardiovascular Electrophysiology, 1995, vol. 6, No. 2, pp. 103-114.
Suzuki et al, “Overexpression of connexin 43 in skeletal myoblasts: relevance to cell transplantation to the heart”, The Journal of Thoracic and Cardiovascular Surgery, 2001, vol. 122, No. 4, pp. 759-766.
American Heart Association. “2001 Heart and Stroke Statistical Update”, Dallas, TX: American Heart Association, 1999.
Atkins, et al. “Cellular cardiomyoplasty improves diastolic properties of injured heart”,J. Surg. Res., (1999) vol. 85: 234-242.
Atkins, et al. “Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium”Cardiac and Vascular Regeneration, (2000) vol. 1: 43-53.
Atkins, et al. Cardiomyoplasty improves diastolic function in a rabbit model of myocardial injury,Circulation, (1998) vol. 98: Supplement 1: 1227.
Atkins, et al. “Intracardiac transplantation of skeletal myoblasts yields two populations of striated cells in situ”,Ann Thorac Surg.(1999) vol. 67: 124-129.
Atkins, et al. “Differential effects of cellular cardiomyoplasty on systolic and diastolic performance in cryoinjured rabbit heart”,J Heart Lung Transpl., (1999) vol. 18: 43.
Atkins, et al. “Transplanted autologous skeletal myoblasts improve myocardial performance after coronary artery ligation”,Cardiac and Vascular Regeneration, (2000) vol. 1: 76-84.
Balogh, et al. “Expression of gap junction in cultured rat L6 cells during myogenesis”,Developmental Biology, (1993) vol. 155: 351-360.
Blau. “Muscling in on gene therapy”,Nature, (1993) vol. 364: 673-675.
Blau, et al. “Myoblasts in pattern formation and gene therapy”,Trends in Genetics, (1993) vol. 9(8): 269-274.
Brittberg, et al. “Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation”,The New England J of Med., (1994) vol. 331: 889-895.
Chiu. “Cardiac cell transplantation: The autologous skeletal myoblast implantation for myocardial regeneration”,Adv Card Surg, (1999) vol. 11: 69-98.
Chiu, et al. “Cellular cardiomyoplasty: Myocardial regeneration with satellite cell implantation”,Ann. Thorac Sug, (1995) vol. 60: 12-18.
Dahl, et al. “Expression of gap junction genes, connexin40 and connexin43, during fetal mouse development”,Anat. Embryol., (1995) vol. 191: 267-278.
Dahl, et al. “Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo”,Proc. Natl. Acad. Sci. USA, vol. 89: 10892-10895.
Dhawan, et al. “Systemic delivery of human growth hormone by injection of genetically engineered myoblasts”,Science, (1991) vol. 254: 1509-1512.
Dorozynski. “Transplanted cells revive heart muscle”,British Medical Journal, (2000) vol. 321(Issue 7268): 1040-1041.
El Oakley, et al. “Myocyte transplantation for myocardial repair: A few good cells can mend a broken heart”,Ann Thorac Surg, (2001) vol. 71(5): 1724-1733.
First ever transplantation of skeletal muscle cells to test whether the cells can repair damaged heart muscle. PR Newswire Sep. 25, 2000. http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-25-2000/00013216663&EDATE=.
Gage, et al. “Genetically modified cells: Applications for intracerebral grafting”,Trends in Neuroscience, (1991) vol. 14(8): 328-333.
GenBank Accession No. AA511201.
GenBank Accession No. AA530689.
GenBank Accession No. AA822279.
GenBank Accession No. AA855990.
GenBank Accession No. AF151980.
GenBank Accession No. AH003191.
GenBank Accession No. M61896.
GenBank Accession No. M65188.
GenBank Accession No. N86403.
GenBank Accession No. NM 000165.
GenBank Accession No. NM 010288.
GenBank Accession No. NM 012567.
GenBank Accession No. X61576.
GenBank Accession No. X62836.
Gussoni, et al. “Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation”,Nature, (1992) vol. 356: 435-438.
Husten. “Global epidemic of cardiovascular disease predicted”,Lancet, (1998) vol. 352: 1530.
Janus, et al. “The modernization of Asia: Implications for coronary heart disease”,Circulation, (1996) vol. 94: 2671-2673.
Kao, et al. “Satellite cell transplantation to repair injured myocardium”,Cardiac and Vascular Regeneration, (2000) vol. 1: 31-42.
Kessler, et al. “Myoblast cell grafting into heart muscle: Cellular biology and potential applications”,Annu Rev Physiol, (1999) vol. 61: 219-242.
Knudsen,
Bozicevic Field & Francis LLP
Francis Carol L.
Li Q. Janice
The Regents of the University of California
LandOfFree
Methods and compositions for correction of cardiac... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for correction of cardiac..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for correction of cardiac... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3870983